285 related articles for article (PubMed ID: 16838598)
1. [Sweden can contribute to safer drug assessment].
Strandberg K
Lakartidningen; 2006 Jun 8-13; 103(23):1853-5. PubMed ID: 16838598
[No Abstract] [Full Text] [Related]
2. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
[No Abstract] [Full Text] [Related]
3. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
Shani S; Yahalom Z
Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
[No Abstract] [Full Text] [Related]
4. Post-marketing surveillance and adverse drug reactions.
Shani S
Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
[No Abstract] [Full Text] [Related]
5. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting.
Lilienfeld DE
Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767
[TBL] [Abstract][Full Text] [Related]
6. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Doshi A
Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
[No Abstract] [Full Text] [Related]
7. Health authorities and drug utilization studies.
Garcia Alonso F; Scott AI; Stika L; Westerholm B
WHO Reg Publ Eur Ser; 1993; 45():147-67. PubMed ID: 8442843
[No Abstract] [Full Text] [Related]
8. [Safer drug handling in hospitals. A new task for the drug committee].
Osterman PO; Gyllenspetz L; Hartvig P; Levol R; Rane A; Söderström A
Lakartidningen; 1996 Oct; 93(44):3917-20. PubMed ID: 8965581
[No Abstract] [Full Text] [Related]
9. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive study.
Meijer WM; Cornel MC; Dolk H; de Walle HE; Armstrong NC; de Jong-van den Berg LT;
Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):675-82. PubMed ID: 16761260
[TBL] [Abstract][Full Text] [Related]
10. Five fixes to improve drug safety. Ideas for how to prevent another Vioxx debacle.
Thygeson M
Minn Med; 2005 Dec; 88(12):36-7. PubMed ID: 16583524
[No Abstract] [Full Text] [Related]
11. [All use of new drugs should be registered. It's the only way to get early warning on unexpected adverse effects].
Werkö L
Lakartidningen; 1999 Oct; 96(40):4284-6. PubMed ID: 10544592
[No Abstract] [Full Text] [Related]
12. Points to consider: the roles of surveillance and epidemiology in advancing drug safety.
Edwards R; Faich G; Tilson H;
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):665-7. PubMed ID: 15719353
[No Abstract] [Full Text] [Related]
13. Development of pharmacovigilance system in Ukraine: first results.
Stefanov O; Sharayeva M; Jajtchenja V
Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):197-9. PubMed ID: 15072120
[TBL] [Abstract][Full Text] [Related]
14. Drug safety--important to us all!
Böttiger LE
J Intern Med; 2001 Oct; 250(4):269-70. PubMed ID: 11576314
[No Abstract] [Full Text] [Related]
15. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
16. Assessment of therapeutic equivalence in drug registration and control.
Idänpään-Heikkilä J
Ann Clin Res; 1974; 6(0):suppl 11:71-8. PubMed ID: 4850672
[No Abstract] [Full Text] [Related]
17. [Does collaboration inside the European Union improve Finnish drug safety?].
Palva E
Duodecim; 2000; 116(24):2810-1. PubMed ID: 12077885
[No Abstract] [Full Text] [Related]
18. [Ranking the efficacy of drugs--a question of "class"? It is difficult to determine equivalency of two different treatments].
Liedholm H; Linné AB
Lakartidningen; 2002 Sep; 99(36):3492-4, 3497-9, 3502. PubMed ID: 12362748
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment of drugs, biologics and therapeutic devices: present and future issues.
Centers for Education and Research on Therapeutics Risk Assessment Workshop
Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):653-62. PubMed ID: 14762981
[TBL] [Abstract][Full Text] [Related]
20. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions.
Moore N; Thiessard F; Begaud B
Pharmacoepidemiol Drug Saf; 2005 Apr; 14(4):285-6. PubMed ID: 15782397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
